OncoMed: Clinical Trial Update (OncoMed) - Jul 17, 2015 - “The primary on target toxicity of OMP-52M51 is diarrhea”; “The MTD of single agent OMP-52M51 has not been reached and dose escalation continues”; “Thus far the half life of OMP-52M51 is approximately 4 days (at 2.5mg/kg Q4W), PK data supports change from a q 28 to q 21 day dosing”; “There is potential evidence of CTC reduction in two patients with baseline > 20 CTCs/mL (mCRC and cholangiocarcinoma) with OMP-52M51 treatment”; “Some suggestion of single agent activity has been noted in a patient with mCRC and a patient with HER2-mBC with stable disease > 120 days”
P1 data • Breast Cancer • Colorectal Cancer • Oncology
|